The RESPECT trial further revealed a 62% relative risk reduction for recurrent cryptogenic ischemic stroke with the Amplatzer PFO Occluder vs medical therapy.1

The RESPECT trial further revealed a 62% relative risk reduction for recurrent cryptogenic ischemic stroke with the Amplatzer PFO Occluder vs medical therapy.1

In addition, there was a 45% relative risk reduction for any recurrent ischemic stroke over nearly 6 years of follow-up, compared to medical therapy.1

In addition, there was a 45% relative risk reduction for any recurrent ischemic stroke over nearly 6 years of follow-up, compared to medical therapy.1
